Company intelligence / Profile preview

CereGate

Ownership: Private
Development stage: Preclinical

Overview

CereGate’s platform has demonstrated the ability to transmit information into the human brain using advanced neuromodulation technology. Its first application focuses on improving gait symptoms for Parkinson’s patients through deep brain stimulation waveforms. The company has achieved FDA Breakthrough designation for its FOG-LIGHTS therapy and launched clinical trials in the US. Additional applications leveraging spinal cord stimulation are being developed to address broader neurological disorders.

Therapeutic areas: Neurology
Modalities: Device (Computer-Brain-Interface/BCI)Software Platform
Industry: Implantable Medical Devices

Beyond the preview

Go deeper on CereGate.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CereGate.

Explore the full profile